诺和诺德的司美格鲁肽,还能再大卖几年?

药事纵横
03 Mar

2025年2月5号,诺德诺德发布2024年年报,其中司美格鲁肽注射液Ozempic®全球销售额为1203.42亿丹麦克朗(约合168.96亿美金),口服司美格鲁肽Rybelsus®全球销售额为233.01亿丹麦克朗(约合32.71亿美金),减肥版司美格鲁肽Wegovy®全球销售额为582.06亿丹麦克朗(约合81.72亿美金),以上三款产品2024年全球销售额共计2018.49亿丹麦克朗,约合...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10